TargetEukaryotic translation initiation factor 2-alpha kinase 3(Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: <16nMAssay Description:Compounds were 3-fold serially diluted in order to obtain from 3.333 to 0.000169 microM final concentration, then incubated for 60 minutes at room te...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3(Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: <16nMAssay Description:Compounds were 3-fold serially diluted in order to obtain from 3.333 to 0.000169 microM final concentration, then incubated for 60 minutes at room te...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3(Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: <16nMAssay Description:Compounds were 3-fold serially diluted in order to obtain from 3.333 to 0.000169 microM final concentration, then incubated for 60 minutes at room te...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3(Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: <16nMAssay Description:Compounds were 3-fold serially diluted in order to obtain from 3.333 to 0.000169 microM final concentration, then incubated for 60 minutes at room te...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3(Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: <16nMAssay Description:Compounds were 3-fold serially diluted in order to obtain from 3.333 to 0.000169 microM final concentration, then incubated for 60 minutes at room te...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3(Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: <16nMAssay Description:Compounds were 3-fold serially diluted in order to obtain from 3.333 to 0.000169 microM final concentration, then incubated for 60 minutes at room te...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3(Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: <16nMAssay Description:Compounds were 3-fold serially diluted in order to obtain from 3.333 to 0.000169 microM final concentration, then incubated for 60 minutes at room te...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3(Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: <16nMAssay Description:Compounds were 3-fold serially diluted in order to obtain from 3.333 to 0.000169 microM final concentration, then incubated for 60 minutes at room te...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3(Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: <16nMAssay Description:Compounds were 3-fold serially diluted in order to obtain from 3.333 to 0.000169 microM final concentration, then incubated for 60 minutes at room te...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3(Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: <16nMAssay Description:Compounds were 3-fold serially diluted in order to obtain from 3.333 to 0.000169 microM final concentration, then incubated for 60 minutes at room te...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3(Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: <16nMAssay Description:Compounds were 3-fold serially diluted in order to obtain from 3.333 to 0.000169 microM final concentration, then incubated for 60 minutes at room te...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3(Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: <16nMAssay Description:Compounds were 3-fold serially diluted in order to obtain from 3.333 to 0.000169 microM final concentration, then incubated for 60 minutes at room te...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3(Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: <16nMAssay Description:Compounds were 3-fold serially diluted in order to obtain from 3.333 to 0.000169 microM final concentration, then incubated for 60 minutes at room te...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3(Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: <16nMAssay Description:Compounds were 3-fold serially diluted in order to obtain from 3.333 to 0.000169 microM final concentration, then incubated for 60 minutes at room te...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3(Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: <16nMAssay Description:Compounds were 3-fold serially diluted in order to obtain from 3.333 to 0.000169 microM final concentration, then incubated for 60 minutes at room te...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3(Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: <16nMAssay Description:Compounds were 3-fold serially diluted in order to obtain from 3.333 to 0.000169 microM final concentration, then incubated for 60 minutes at room te...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3(Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 33nMAssay Description:Compounds were 3-fold serially diluted in order to obtain from 3.333 to 0.000169 microM final concentration, then incubated for 60 minutes at room te...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3(Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 33nMAssay Description:Compounds were 3-fold serially diluted in order to obtain from 3.333 to 0.000169 microM final concentration, then incubated for 60 minutes at room te...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3(Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 33nMAssay Description:Compounds were 3-fold serially diluted in order to obtain from 3.333 to 0.000169 microM final concentration, then incubated for 60 minutes at room te...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3(Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 33nMAssay Description:Compounds were 3-fold serially diluted in order to obtain from 3.333 to 0.000169 microM final concentration, then incubated for 60 minutes at room te...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3(Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 33nMAssay Description:Compounds were 3-fold serially diluted in order to obtain from 3.333 to 0.000169 microM final concentration, then incubated for 60 minutes at room te...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3(Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 33nMAssay Description:Compounds were 3-fold serially diluted in order to obtain from 3.333 to 0.000169 microM final concentration, then incubated for 60 minutes at room te...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3(Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 33nMAssay Description:Compounds were 3-fold serially diluted in order to obtain from 3.333 to 0.000169 microM final concentration, then incubated for 60 minutes at room te...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3(Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 33nMAssay Description:Compounds were 3-fold serially diluted in order to obtain from 3.333 to 0.000169 microM final concentration, then incubated for 60 minutes at room te...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3(Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 33nMAssay Description:Compounds were 3-fold serially diluted in order to obtain from 3.333 to 0.000169 microM final concentration, then incubated for 60 minutes at room te...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3(Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 33nMAssay Description:Compounds were 3-fold serially diluted in order to obtain from 3.333 to 0.000169 microM final concentration, then incubated for 60 minutes at room te...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3(Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 33nMAssay Description:Compounds were 3-fold serially diluted in order to obtain from 3.333 to 0.000169 microM final concentration, then incubated for 60 minutes at room te...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3(Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 33nMAssay Description:Compounds were 3-fold serially diluted in order to obtain from 3.333 to 0.000169 microM final concentration, then incubated for 60 minutes at room te...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3(Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 33nMAssay Description:Compounds were 3-fold serially diluted in order to obtain from 3.333 to 0.000169 microM final concentration, then incubated for 60 minutes at room te...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3(Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 33nMAssay Description:Compounds were 3-fold serially diluted in order to obtain from 3.333 to 0.000169 microM final concentration, then incubated for 60 minutes at room te...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3(Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 33nMAssay Description:Compounds were 3-fold serially diluted in order to obtain from 3.333 to 0.000169 microM final concentration, then incubated for 60 minutes at room te...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3(Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 33nMAssay Description:Compounds were 3-fold serially diluted in order to obtain from 3.333 to 0.000169 microM final concentration, then incubated for 60 minutes at room te...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3(Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 33nMAssay Description:Compounds were 3-fold serially diluted in order to obtain from 3.333 to 0.000169 microM final concentration, then incubated for 60 minutes at room te...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3(Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 33nMAssay Description:Compounds were 3-fold serially diluted in order to obtain from 3.333 to 0.000169 microM final concentration, then incubated for 60 minutes at room te...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3(Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 33nMAssay Description:Compounds were 3-fold serially diluted in order to obtain from 3.333 to 0.000169 microM final concentration, then incubated for 60 minutes at room te...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3(Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 33nMAssay Description:Compounds were 3-fold serially diluted in order to obtain from 3.333 to 0.000169 microM final concentration, then incubated for 60 minutes at room te...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3(Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 33nMAssay Description:Compounds were 3-fold serially diluted in order to obtain from 3.333 to 0.000169 microM final concentration, then incubated for 60 minutes at room te...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3(Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 33nMAssay Description:Compounds were 3-fold serially diluted in order to obtain from 3.333 to 0.000169 microM final concentration, then incubated for 60 minutes at room te...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3(Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 33nMAssay Description:Compounds were 3-fold serially diluted in order to obtain from 3.333 to 0.000169 microM final concentration, then incubated for 60 minutes at room te...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3(Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 33nMAssay Description:Compounds were 3-fold serially diluted in order to obtain from 3.333 to 0.000169 microM final concentration, then incubated for 60 minutes at room te...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3(Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 33nMAssay Description:Compounds were 3-fold serially diluted in order to obtain from 3.333 to 0.000169 microM final concentration, then incubated for 60 minutes at room te...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3(Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 33nMAssay Description:Compounds were 3-fold serially diluted in order to obtain from 3.333 to 0.000169 microM final concentration, then incubated for 60 minutes at room te...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3(Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 33nMAssay Description:Serially diluted compounds were incubated for 60 minutes at room temperature in the presence of ATP/P33 gammaATP mix, substrate and enzyme in a volum...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3(Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 33nMAssay Description:Serially diluted compounds were incubated for 60 minutes at room temperature in the presence of ATP/P33 gammaATP mix, substrate and enzyme in a volum...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3(Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 33nMAssay Description:Compounds were 3-fold serially diluted in order to obtain from 3.333 to 0.000169 microM final concentration, then incubated for 60 minutes at room te...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3(Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 33nMAssay Description:Compounds were 3-fold serially diluted in order to obtain from 3.333 to 0.000169 microM final concentration, then incubated for 60 minutes at room te...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3(Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 105nMAssay Description:Compounds were 3-fold serially diluted in order to obtain from 3.333 to 0.000169 microM final concentration, then incubated for 60 minutes at room te...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3(Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 105nMAssay Description:Compounds were 3-fold serially diluted in order to obtain from 3.333 to 0.000169 microM final concentration, then incubated for 60 minutes at room te...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3(Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 105nMAssay Description:Compounds were 3-fold serially diluted in order to obtain from 3.333 to 0.000169 microM final concentration, then incubated for 60 minutes at room te...More data for this Ligand-Target Pair
TargetEukaryotic translation initiation factor 2-alpha kinase 3(Homo sapiens (Human))
Nerviano Medical Sciences
US Patent
Nerviano Medical Sciences
US Patent
Affinity DataIC50: 105nMAssay Description:Compounds were 3-fold serially diluted in order to obtain from 3.333 to 0.000169 microM final concentration, then incubated for 60 minutes at room te...More data for this Ligand-Target Pair